BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32517333)

  • 21. Contribution of epitope specificity to the binding of monoclonal antibodies to the capsule of Cryptococcus neoformans and the soluble form of its major polysaccharide, glucuronoxylomannan.
    Duro RM; Netski D; Thorkildson P; Kozel TR
    Clin Diagn Lab Immunol; 2003 Mar; 10(2):252-8. PubMed ID: 12626451
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure of the O-deacetylated glucuronoxylomannan from Cryptococcus neoformans Cap70 as determined by 2D NMR spectroscopy.
    Bacon BE; Cherniak R; Kwon-Chung KJ; Jacobson ES
    Carbohydr Res; 1996 Mar; 283():95-110. PubMed ID: 8901265
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis.
    Cherniak R; Morris LC; Belay T; Spitzer ED; Casadevall A
    Infect Immun; 1995 May; 63(5):1899-905. PubMed ID: 7729900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunoelectronmicroscopic characterization of monoclonal antibodies (MAbs) against Cryptococcus neoformans.
    Todaro-Luck F; White EH; Reiss E; Cherniak R
    Mol Cell Probes; 1989 Dec; 3(4):345-61. PubMed ID: 2482437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phenotypic heterogeneity in expression of epitopes in the Cryptococcus neoformans capsule.
    Gates-Hollingsworth MA; Kozel TR
    Mol Microbiol; 2009 Oct; 74(1):126-138. PubMed ID: 19758241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chitin-like molecules associate with Cryptococcus neoformans glucuronoxylomannan to form a glycan complex with previously unknown properties.
    Ramos CL; Fonseca FL; Rodrigues J; GuimarĂ£es AJ; Cinelli LP; Miranda K; Nimrichter L; Casadevall A; Travassos LR; Rodrigues ML
    Eukaryot Cell; 2012 Sep; 11(9):1086-94. PubMed ID: 22562469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity.
    Devi SJ; Schneerson R; Egan W; Ulrich TJ; Bryla D; Robbins JB; Bennett JE
    Infect Immun; 1991 Oct; 59(10):3700-7. PubMed ID: 1716613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structure of the O-deacetylated glucuronoxylomannan from Cryptococcus neoformans serotype C as determined by 2D 1H NMR spectroscopy.
    Bacon BE; Cherniak R
    Carbohydr Res; 1995 Oct; 276(2):365-86. PubMed ID: 8542606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of Cryptococcus neoformans capsular glucuronoxylomannan polysaccharide with monoclonal antibodies.
    Todaro-Luck F; Reiss E; Cherniak R; Kaufman L
    Infect Immun; 1989 Dec; 57(12):3882-7. PubMed ID: 2680986
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monoclonal antibodies specific for immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, reduce serotype bias in an immunoassay for cryptococcal antigen.
    Percival A; Thorkildson P; Kozel TR
    Clin Vaccine Immunol; 2011 Aug; 18(8):1292-6. PubMed ID: 21697342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reactivity patterns and epitope specificities of anti-Cryptococcus neoformans monoclonal antibodies by enzyme-linked immunosorbent assay and dot enzyme assay.
    Belay T; Cherniak R; Kozel TR; Casadevall A
    Infect Immun; 1997 Feb; 65(2):718-28. PubMed ID: 9009335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice.
    Maitta RW; Datta K; Lees A; Belouski SS; Pirofski LA
    Infect Immun; 2004 Jan; 72(1):196-208. PubMed ID: 14688097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles.
    Maitta RW; Datta K; Chang Q; Luo RX; Witover B; Subramaniam K; Pirofski LA
    Infect Immun; 2004 Aug; 72(8):4810-8. PubMed ID: 15271943
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glucuronoxylomannan of Cryptococcus neoformans serotype B: structural analysis by gas-liquid chromatography-mass spectrometry and 13C-nuclear magnetic resonance spectroscopy.
    Turner SH; Cherniak R
    Carbohydr Res; 1991 Apr; 211(1):103-16. PubMed ID: 1773425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structural studies of the capsular polysaccharide of a non-neoformans Cryptococcus species identified as C. laurentii, which was reclassified as Cryptococcus flavescens, from a patient with AIDS.
    Ikeda R; Maeda T
    Carbohydr Res; 2004 Feb; 339(3):503-9. PubMed ID: 15013387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular and idiotypic analysis of antibodies to Cryptococcus neoformans glucuronoxylomannan.
    Casadevall A; DeShaw M; Fan M; Dromer F; Kozel TR; Pirofski LA
    Infect Immun; 1994 Sep; 62(9):3864-72. PubMed ID: 8063403
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Self-aggregation of Cryptococcus neoformans capsular glucuronoxylomannan is dependent on divalent cations.
    Nimrichter L; Frases S; Cinelli LP; Viana NB; Nakouzi A; Travassos LR; Casadevall A; Rodrigues ML
    Eukaryot Cell; 2007 Aug; 6(8):1400-10. PubMed ID: 17573547
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contribution of the mannan backbone of cryptococcal glucuronoxylomannan and a glycolytic enzyme of Staphylococcus aureus to contact-mediated killing of Cryptococcus neoformans.
    Ikeda R; Saito F; Matsuo M; Kurokawa K; Sekimizu K; Yamaguchi M; Kawamoto S
    J Bacteriol; 2007 Jul; 189(13):4815-26. PubMed ID: 17483230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Paracoccidioides brasiliensis glycan shares serologic and functional properties with cryptococcal glucuronoxylomannan.
    Albuquerque PC; Cordero RJ; Fonseca FL; Peres da Silva R; Ramos CL; Miranda KR; Casadevall A; Puccia R; Nosanchuk JD; Nimrichter L; Guimaraes AJ; Rodrigues ML
    Fungal Genet Biol; 2012 Nov; 49(11):943-54. PubMed ID: 23010152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fc-dependent and Fc-independent opsonization of Cryptococcus neoformans by anticapsular monoclonal antibodies: importance of epitope specificity.
    Netski D; Kozel TR
    Infect Immun; 2002 Jun; 70(6):2812-9. PubMed ID: 12010967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.